Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note.

@article{Bilchik2005NeoadjuvantCF,
  title={Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note.},
  author={Anton J. Bilchik and Graeme Poston and Steven A. Curley and Steven M. Strasberg and Leonard B. Saltz and Ren{\'e} Adam and Bernard M. Nordlinger and Philippe Rougier and Lee S. Rosen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 36},
  pages={
          9073-8
        }
}
  • A. Bilchik, G. Poston, +6 authors L. Rosen
  • Published 20 December 2005
  • Art
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Anton J. Bilchik, John Wayne Cancer Institute at St John’s Health Center, Santa Monica, CA Graeme Poston, Royal Liverpool and Aintree University Hospitals, Liverpool, UK Steven A. Curley, The University of Texas M.D. Anderson Cancer Center, Houston, TX Steven Strasberg, Siteman Cancer Center at Washington University in St Louis, St Louis, MO Leonard Saltz, Memorial Sloan Kettering Cancer Center, New York, NY Rene Adam, Paul Brousse Hospital, Paris, France Bernard Nordlinger and Philippe Rougier… 
View on PubMed
docum-enter.com
136 Citations
Highly Influential Citations
5
Background Citations
47
Methods Citations
2
Results Citations
3

136 Citations

Citation Type

Citation Type

Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm.
TLDR
This study highlights the need to understand more fully the pre- and post-operative role of chemotherapy in the development of central giant cell granuloma and its role in the immune response.
Colon Cancer , Version 3 . 2014 Clinical Practice Guidelines in Oncology
TLDR
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship, focusing mainly on systemic therapy.
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy.
Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial
TLDR
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent.
  • H. Lenz
  • Medicine
    Cancer treatment reviews
  • 2008
Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement by Bartlett et al.
TLDR
The authors discussed the challenge of optimizing any chemotherapeutic approach given the recent, almost simultaneous, regulatory approval of a number of novel biologic agents and the potential of some, if not all, of these to cause liver damage, which in turn may adversely affect a patient s ability to survive a potentially curative liver resection.
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective
  • Y. Shimada
  • Medicine
    Journal of hepato-biliary-pancreatic sciences
  • 2012
TLDR
Indications for liver resection after neo-adjuvant chemotherapy; optimal chemotherapy regimens; and histological changes in the normal liver are important research issues for the future.
Adjuvant therapy for resectable liver metastases: Can metastatic colorectal cancer be cured?
TLDR
Individuals should be encouraged to participate in clinical trials to help clarify the role and optimal sequencing of systemic chemotherapy, targeted agents, local therapies, and surgery for patients with hepatic metastases from colorectal cancer.
Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases
TLDR
This review examines approaches to the neoadjuvant management of colorectal liver metastases with systemic therapies and the addition of biologic therapies has further enhanced antitumor response, resulting in successful disease resection in certain patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
TLDR
Sinusoidal obstruction, complicated by perisinusoidal fibrosis and veno-occlusive lesion of the non-tumoral liver revealed by this study, should be included in the list of the adverse side-effects of colorectal systemic chemotherapy, in particular related to the use of oxaliplatin.
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
  • G. Poston
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2005
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
TLDR
Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
TLDR
Preliminary results indicate that the TIP chemotherapy regimen produced high rates of major responses in patients with recurrent or metastatic head and neck squamous cell carcinoma, and responses were durable.
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
TLDR
Resection of metastatic disease after chemotherapy is possible in a small but important subset of patients with MCRC, particularly after receiving an oxaliplatin-based chemotherapy regimen, with encouraging OS and TTP observed in these highly selected patients.
Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy.
TLDR
Results show that the resection of previously unresectable metastases became possible in up to 16% of patients after chemotherapy with a chronomodulated regimen of oxaliplatin plus 5-fluorouracil/folinic acid, demonstrating that this new approach can significantly prolong survival for patients with a previously bleak outlook.
FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial.
  • T. Hickish, C. Boni, +7 authors A. de Gramont
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
In the FOLFOX4 arm of MOSAIC, stage II patients benefited from a 20% relative reduction in the risk of recurrence versus those of the LV5FU2 arm with a limited incidence of major safety events.
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Oxaliplatin Toxicity Masquerading As Recurrent Colon Cancer
TLDR
Having tested the entire cohort of 1,035 high-risk individuals enrolled onto the authors' pilot trial, it will be assessed in the near future if very small computed tomography – detected lung cancers show a level of DNA release into plasma similar to the one observed in symptomatic patients with NSCLC, thus demonstrating the real contribution of this polymerase chain reaction assay to early lung cancer detection.
Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival
TLDR
Modern chemotherapy allows 12.5% of patients with unresectable CRLM to be rescued by liver surgery, with a wide use of repeat hepatectomies and extrahepatic resections, and four preoperative risk factors could select the patients most likely to benefit from this strategy.
...
1
2
3
4
...